Avances en el manejo del Trastorno Disfórico Premenstrual

Authors

DOI:

https://doi.org/10.59706/aebmedicine.v1i2.8665

Keywords:

Fase luteínica, Terapias complementarias, Trastorno Disfórico Premenstrual

Abstract

El Trastorno Disfórico Premenstrual (TDPM) incluye una constelación de síntomas físicos, cognitivos y/o afectivos que aparecen en la fase luteínica del ciclo menstrual y remite con la menstruación. Las etiología se desconoce en su mayoría pero las teorías más aceptadas se relacionan con la respuesta alterada del eje hipotálamo-hipófisis-gónadas, la hiposensibilidad de los receptores GABA-a a alopregnanolona y el desequilibrio en la serotonina, sistema inmune, calcio y del ciclo circadiano. Las manifestaciones son lo suficientemente severas para interferir con las actividades de la vida diaria. El tratamiento de primera línea incluye a los cambios en el estilo de vida, inhibidores selectivos de la recaptación de serotonina (ISRS), anticonceptivos hormonales combinados y las benzodiacepinas. Esta revisión narrativa de la literatura expone las terapias complementarias no farmacológicas con mayor evidencia cómo el ejercicio, la terapia cognitivo conductual, la suplementación de vitaminas y minerales, las técnicas de relajación, los fitofármacos, ademásde las terapias farmacológicas más novedosas.

Downloads

Download data is not yet available.

Author Biographies

Juan Pablo Zamanillo Tanús

Médico Pasante del Servicio Social del Instituto Tecnológico y de Estudios Superiores de Monterrey, Campus Guadalajara, Jalisco, México.

Sergio Enrique Medina Barragán

Médico Interno de Pregrado del Instituto Tecnológico y de Estudios Superiores de Monterrey, Campus Guadalajara, Jalisco, México.

Assurian Mariett Zambrano Pelayo

Médico Residente de cuarto año, Hospital San Juan de Dios, Zapopan, Jalisco, México.

Erendira Aracelis Cedeño Meza

Médico Residente de cuarto año, Hospital San Juan de Dios, Zapopan, Jalisco, México.

References

Abdollahifard, S., Rahmanian Koshkaki, A., & Moazamiyanfar, R. (2014). The effects of vitamin B1 on ameliorating the premenstrual syndrome symptoms. Global journal of health science, 6(6), 144–153. https://doi.org/10.5539/gjhs.v6n6p144

American Academy of Pediatrics. (2016). Neonatal morbidity after maternal use of antidepressant drugs during pregnancy. Pediatrics, 137(5), e20160181. https://doi.org/10.1542/peds.2016-0181

American College of Obstetricians and Gynecologists. (2023). Management of premenstrual disorders: ACOG clinical practice guideline no. 7. Obstetrics & Gynecology, 142(6), 1516-1533. https://doi.org/10.1097/AOG.0000000000005426

American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). https://doi.org/10.1176/appi.books.9780890425596

Armour, M., Ee, C. C., Hao, J., Wilson, T. M., Yao, S. S., & Smith, C. A. (2018). Acupuncture and acupressure for premenstrual syndrome. En Cochrane Database of Systematic Reviews (Vol. 2018, Número 8). John Wiley and Sons Ltd. https://doi.org/10.1002/14651858.CD005290.pub2

Askari, S., Behroozi, N., & Abbaspoor, Z. (2018). The effect of mindfulness-based cognitive-behavioral therapy on premenstrual syndrome. Iranian Red Crescent Medical Journal, 20(2). https://doi.org/10.5812/ircmj.57538

Bäckström, T., Ekberg, K., Hirschberg, A. L., Bixo, M., Epperson, C. N., Briggs, P., Panay, N., & O’Brien, S. (2021). A randomized, double-blind study on efficacy and safety of sepranolone in premenstrual dysphoric disorder. Psychoneuroendocrinology, 133. https://doi.org/10.1016/j.psyneuen.2021.105426

Bixo, M., Ekberg, K., Poromaa, I. S., Hirschberg, A. L., Jonasson, A. F., Andréen, L., Timby, E., Wulff, M., Ehrenborg, A., & Bäckström, T. (2017). Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)—A randomized controlled trial. Psychoneuroendocrinology, 80, 46–55. https://doi.org/10.1016/j.psyneuen.2017.02.031

Carlini, S. V., & Deligiannidis, K. M. (2020). Evidence-based treatment of premenstrual dysphoric disorder: A concise review. En Journal of Clinical Psychiatry (Vol. 81, Número 2). Physicians Postgraduate Press Inc. https://doi.org/10.4088/JCP.19ac13071

Carlini, S. V., Di Scalea, T. L., McNally, S. T., Lester, J., & Deligiannidis, K. M. (2022). Management of Premenstrual Dysphoric Disorder: A Scoping Review. En International Journal of Women’s Health (Vol. 14, pp. 1783–1801). Dove Medical Press Ltd. https://doi.org/10.2147/IJWH.S297062

Casper, R. F., & Hearn, M. T. (1990). The effect of hysterectomy and bilateral oophorectomy in women with severe premenstrual syndrome. American Journal of Obstetrics and Gynecology, 162(1), 105–109. https://doi.org/10.1016/0002-9378(90)90831-Q

Cohen, L. S., Soares, C. N., Yonkers, K. A., Bellew, K. M., Bridges, I. M., & Steiner, M. (2004). Paroxetine controlled release for premenstrual dysphoric disorder: A double-blind, placebo-controlled trial. Psychosomatic Medicine, 66(5), 707–713. https://doi.org/10.1097/01.psy.0000140005.94790.9c

Comasco, E., Kallner, H. K., Bixo, M., Hirschberg, A. L., Nyback, S., De Grauw, H., Epperson, C. N., & Sundström-Poromaa, I. (2021). Ulipristal acetate for treatment of premenstrual dysphoric disorder: A proof-of-concept randomized controlled trial. American Journal of Psychiatry, 178(3), 256–265. https://doi.org/10.1176/appi.ajp.2020.20030286

Crowley, S. K., & Girdler, S. S. (2014). Neurosteroid, GABAergic and hypothalamic pituitary adrenal (HPA) axis regulation: what is the current state of knowledge in humans? Psychopharmacology (Berl), 231(17), 3619-34. DOI: 10.1007/s00213-014-3572-8

Dawood, M. Y., Ramos, J., & Khan-Dawood, F. S. (1995). Depot leuprolide acetate versus danazol for treatment of pelvic endometriosis: Changes in vertebral bone mass and serum estradiol and calcitonin. Fertility and Sterility, 63(6), 1177–1183. https://doi.org/10.1016/s0015-0282(16)57593-1

Dennerstein, L., Lehert, P., Keung, L. S., Pal, S. A., & Choi, D. (2010). Asian study of effects of premenstrual symptoms on activities of daily life. Menopause International, 16(4), 146–151. https://doi.org/10.1258/mi.2010.010035

Direkvand-Moghadam, A., Sayehmiri, K., Delpisheh, A., & Satar, K. (2014). Epidemiology of premenstrual syndrome, a systematic review and meta-analysis study. Journal of Clinical and Diagnostic Research, 8(2), 106–109. https://doi.org/10.7860/JCDR/2014/8024.4021

Duvan, C. I., Cumaoglu, A., Turhan, N. O., Karasu, C., & Kafali, H. (2011). Oxidant/antioxidant status in premenstrual syndrome. Archives of Gynecology and Obstetrics, 283(2), 299–304. https://doi.org/10.1007/s00404-009-1347-y

Eriksson, E., Ekman, A., Sinclair, S., Sörvik, K., Ysander, C., Mattson, U. B., & Nissbrandt, H. (2008). Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder. Journal of Clinical Psychopharmacology, 28(2), 195–202. https://doi.org/10.1097/JCP.0b013e3181678a28

Eter, P., Chmidt, J. S., Ieman, Y. K. N., Anaceau, E. A. D., Inda, L., Dams, F. A., Avid, D., & Ubinow, R. R. (1998). The New England Journal of Medicine Differential Behavioral Effects Of Gonadal Steroids In Women With And In Those Without Premenstrual Syndrome Abstract Background The symptoms of women with pre (Vol. 338).

Frankel, R. A., Michels, K. A., Kim, K., Kuhr, D. L., Omosigho, U. R., Wactawski-Wende, J., Levine, L., Perkins, N. J., & Mumford, S. L. (2021). Serum antioxidant vitamin concentrations and oxidative stress markers associated with symptoms and severity of premenstrual syndrome: a prospective cohort study. BMC Women’s Health, 21(1). https://doi.org/10.1186/s12905-021-01187-7

Freeman, E. W., Rickels, K., Sondheimer, S. J., Polansky, M., Freeman, G., & Freeman, P. (1995). A Double-blind Trial of Oral Progesterone, Alprazolam, and Placebo in Treatment of Severe Premenstrual Syndrome From the Departments of Obstetrics and. http://jama.jamanetwork.com/

Freeman, E. W., Rickels, K., Sondheimer, S. J., Polansky, M., & Sha Xiao, S. (2004). Continuous or Intermittent Dosing With Sertraline for Patients With Severe Premenstrual Syndrome or Premenstrual Dysphoric Disorder. En Am J Psychiatry (Vol. 161, Número 2). http://ajp.psychiatryonline.org

Freeman, E. W., Rickels, K., Yonkers, K. A., Kunz, N. R., Mcpherson, M., & Upton, G. V. (2001). Venlafaxine in the Treatment of Premenstrual Dysphoric Disorder.

Green LJ, O’Brien PMS, Panay N, Craig M on behalf of the Royal College of Obstetricians and Gynaecologists Management of premenstrual syndrome. BJOG 2016; DOI: 10.1111/1471-0528.14260.

Grigoriadis, S., VonderPorten, E. H., Mamisashvili, L., Roerecke, M., Rehm, J., Dennis, C. L., Koren, G., Steiner, M., Mousmanis, P., Cheung, A., & Ross, L. E. (2013). Antidepressant exposure during pregnancy and congenital malformations: Is there an association? A systematic review and meta-analysis of the best evidence. En Journal of Clinical Psychiatry (Vol. 74, Número 4). Physicians Postgraduate Press Inc. https://doi.org/10.4088/JCP.12r07966

Grigoriadis, S., VonderPorten, E. H., Mamisashvili, L., Eady, A., Tomlinson, G., Dennis, C.-L., Koren, G., Steiner, M., Mousmanis, P., Cheung, A., & Ross, L. E. (2013). The effect of prenatal antidepressant exposure on neonatal adaptation: a systematic review and meta-analysis. The Journal of Clinical Psychiatry, 74(4), e309-e320. https://doi.org/10.4088/JCP.12r07967

Halbreich, U., Borenstein, J., Pearlstein, T., & Kahn, L. S. (2003). The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology, 28(SUPPL. 3), 1–23. https://doi.org/10.1016/S0306-4530(03)00098-2

Hasanpour, M., Mohammadi, M. M., & Shareinia, H. (2019). Effects of reflexology on premenstrual syndrome: A systematic review and meta-analysis. En BioPsychoSocial Medicine (Vol. 13, Número 1). BioMed Central Ltd. https://doi.org/10.1186/s13030-019-0165-0

Hofmeister, S., & Bodden, S. (2016). Premenstrual Syndrome and Premenstrual Dysphoric Disorder (Vol. 94). www.aafp.org/afp.

Itriyeva, K. (2022). Premenstrual syndrome and premenstrual dysphoric disorder in adolescents. Current Problems in Pediatric and Adolescent Health Care, 52(5). https://doi.org/10.1016/j.cppeds.2022.101187

Jafari, F., Amani, R., & Tarrahi, M. J. (2020). Effect of Zinc Supplementation on Physical and Psychological Symptoms, Biomarkers of Inflammation, Oxidative Stress, and Brain-Derived Neurotrophic Factor in Young Women with Premenstrual Syndrome: a Randomized, Double-Blind, Placebo-Controlled Trial. Biological Trace Element Research, 194(1), 89–95. https://doi.org/10.1007/s12011-019-01757-9

Joffe, H., Cohen, L. S., & Harlow, B. L. (2003). Impact of oral contraceptive pill use on premenstrual mood: Predictors of improvement and deterioration. American Journal of Obstetrics and Gynecology, 189(6), 1523–1530. https://doi.org/10.1016/S0002-9378(03)00927-X

Kancheva Landolt, N., & Ivanov, K. (2021). Short report: cognitive behavioral therapy - a primary mode for premenstrual syndrome management: systematic literature review. Psychology, Health and Medicine, 26(10), 1282–1293. https://doi.org/10.1080/13548506.2020.1810718

Lanza di Scalea, T., & Pearlstein, T. (2019). Premenstrual Dysphoric Disorder. En Medical Clinics of North America (Vol. 103, Número 4, pp. 613–628). W.B. Saunders. https://doi.org/10.1016/j.mcna.2019.02.007

Lukes, A. S., McBride, R. J., Herring, A. H., Fried, M., Sherwani, A., & Dell, D. (2011). Improved Premenstrual Syndrome Symptoms after NovaSure Endometrial Ablation. Journal of Minimally Invasive Gynecology, 18(5), 607–611. https://doi.org/10.1016/j.jmig.2011.06.001

Marr, J., Niknian, M., Shulman, L. P., & Lynen, R. (2011). Premenstrual dysphoric disorder symptom cluster improvement by cycle with the combined oral contraceptive ethinylestradiol 20 mcg plus drospirenone 3 mg administered in a 24/4 regimen. Contraception, 84(1), 81–86. https://doi.org/10.1016/j.contraception.2010.10.010

Meltzer-Brody, S., Colquhoun, H., Riesenberg, R., Epperson, C. N., Deligiannidis, K. M., Rubinow, D. R., Li, H., Sankoh, A. J., Clemson, C., Schacterle, A., Jonas, J., & Kanes, S. (2018). Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. The Lancet, 392(10152), 1058–1070. https://doi.org/10.1016/S0140-6736(18)31551-4

Moderie, C., Boudreau, P., Shechter, A., Lespérance, P., & Boivin, D. B. (2021). Effects of exogenous melatonin on sleep and circadian rhythms in women with premenstrual dysphoric disorder. Sleep, 44(12). https://doi.org/10.1093/sleep/zsab171

Mohebbi Dehnavi, Z., Jafarnejad, F., & Sadeghi Goghary, S. (2018). The effect of 8weeks aerobic exercise on severity of physical symptoms of premenstrual syndrome: A clinical trial study. BMC Women’s Health, 18(1). https://doi.org/10.1186/s12905-018-0565-5

Nevatte, T., O’Brien, P. M. S., Bäckström, T., Brown, C., Dennerstein, L., Endicott, J., Epperson, C. N., Eriksson, E., Freeman, E. W., Halbreich, U., Ismail, K., Panay, N., Pearlstein, T., Rapkin, A., Reid, R., Rubinow, D., Schmidt, P., Steiner, M., Studd, J., … Yonkers, K. (2013). ISPMD consensus on the management of premenstrual disorders. Archives of Women’s Mental Health, 16(4), 279–291. https://doi.org/10.1007/s00737-013-0346-y

Pearce, E., Jolly, K., Jones, L. L., Matthewman, G., Zanganeh, M., & Daley, A. (2020). Exercise for premenstrual syndrome: A systematic review and meta-analysis of randomised controlled trials. BJGP Open, 4(3). https://doi.org/10.3399/bjgpopen20X101032

Prasad, A. S. (2014). Zinc: An antioxidant and anti-inflammatory agent: Role of zinc in degenerative disorders of aging. En Journal of Trace Elements in Medicine and Biology (Vol. 28, Número 4, pp. 364–371). Elsevier GmbH. https://doi.org/10.1016/j.jtemb.2014.07.019

Rajabi, F., Rahimi, M., Sharbafchizadeh, M. R., & Tarrahi, M. J. (2020). Saffron for the Management of Premenstrual Dysphoric Disorder: A Randomized Controlled Trial. Advanced Biomedical Research, 9(1), 60. https://doi.org/10.4103/abr.abr_49_20

Rapkin, A. J., & Mikacich, J. A. (2013). Premenstrual dysphoric disorder and severe premenstrual syndrome in adolescents: Diagnosis and pharmacological treatment. En Pediatric Drugs (Vol. 15, Número 3, pp. 191–202). https://doi.org/10.1007/s40272-013-0018-4

Reid, R. L. (2012). When should surgical treatment be considered for premenstrual dysphoric disorder? En Menopause International (Vol. 18, Número 2, pp. 77–81). https://doi.org/10.1258/mi.2012.012009

Sears, S. M., & Hewett, S. J. (2021). Influence of glutamate and GABA transport on brain excitatory/inhibitory balance. Experimental Biology and Medicine, 246(8), 1069–1083. https://doi.org/10.1177/1535370221989263

Shechter, A., Lespérance, P., Ng Ying Kin, N. M. K., & Boivin, D. B. (2012). Nocturnal polysomnographic sleep across the menstrual cycle in premenstrual dysphoric disorder. Sleep Medicine, 13(8), 1071–1078. https://doi.org/10.1016/j.sleep.2012.05.012

Shobeiri, F., Araste, F. E., Ebrahimi, R., Jenabi, E., & Nazari, M. (2017). Effect of calcium on premenstrual syndrome: A double-blind randomized clinical trial. Obstetrics and Gynecology Science, 60(1), 100–105. https://doi.org/10.5468/ogs.2017.60.1.100

Steinberg, E. M., Cardoso, G. M. P., Martinez, P. E., Rubinow, D. R., & Schmidt, P. J. (2012). Rapid response to fluoxetine in women with premenstrual dysphoric disorder. Depression and Anxiety, 29(6), 531–540. https://doi.org/10.1002/da.21959

Tiranini, L., & Nappi, R. E. (2022). Recent advances in understanding/management of premenstrual dysphoric disorder/premenstrual syndrome. Faculty Reviews, 11. https://doi.org/10.12703/r/11-11

Wittchen, H.-U., Becker, " E, Lieb, R., & Krause, P. (2002). Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychological Medicine, 32, 119–132. https://doi.org/10.1017S0033291701004925

Wyatt, K. M., Dimmock, P. W., Frischer, M., Jones, P. W., & Pm O’brien, S. (2002). Prescribing patterns in premenstrual syndrome. http://www.biomedcentral.com/1472-6874/2/4

Wyatt, K. M., Dimmock, P. W., Ismail, K. M. K., Jones, P. W., & Shaughn O’brien, P. M. (2004). The effectiveness of GnRHa with and without “add-back” therapy in treating premenstrual syndrome: a meta analysis. www.blackwellpublishing.com/bjog

Wyatt, K. M., Dimmock, P. W., Jones, P. W., & O’brien, P. M. S. (1999). Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: Systematic review. BMJ, 318(7195), 1375–1381. https://doi.org/10.1136/bmj.318.7195.1375

Yan, H., Ding, Y., & Guo, W. (2021). Suicidality in patients with premenstrual dysphoric disorder–A systematic review and meta-analysis. En Journal of Affective Disorders (Vol. 295, pp. 339–346). Elsevier B.V. https://doi.org/10.1016/j.jad.2021.08.082

Yesildere Saglam, H., & Orsal, O. (2020). Effect of exercise on premenstrual symptoms: A systematic review. En Complementary Therapies in Medicine (Vol. 48). Churchill Livingstone. https://doi.org/10.1016/j.ctim.2019.102272

Yonkers, K. A., Halbreich, U., Freeman, E., Brown, C., Endicott, J., Frank, E., Parry, B., Pearlstein, T., Severino, S., Stout, A., Stone, A., & Harrison, W. (1997). Symptomatic Improvement of Premenstrual Dysphoric Disorder With Sertraline Treatment A Randomized Controlled Trial Daily Record of Severity of Problems, Hamilton Rating Scale for Depression, Clinical Global Impression Scale, and Social Adjustment Scale. http://jama.jamanetwork.com/

Zhang, J., Cao, L., Wang, Y., Jin, Y., Xiao, X., & Zhang, Q. (2019). Acupuncture for Premenstrual Syndrome at Different Intervention Time: A Systemic Review and Meta-Analysis. Evidence-based Complementary and Alternative Medicine, 2019. https://doi.org/10.1155/2019/6246285

Premenstrual

Downloads

Published

2023-12-29

How to Cite

Guzmán Castellanos, J. F., Zamanillo Tanús, J. P., Medina Barragán, S. E., Zambrano Pelayo , A. M., & Cedeño Meza , E. A. (2023). Avances en el manejo del Trastorno Disfórico Premenstrual. Archives of Evidence-Based Medicine, 1(2), 12–24. https://doi.org/10.59706/aebmedicine.v1i2.8665

Issue

Section

Reviews

Plaudit